Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bromelain + rutoside + trypsin
- Development stage
- Unknown
- Lead developer
- Anglo-French Drugs & Industries
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
Rednil is an oral fixed-dose combination tablet containing the proteolytic enzymes bromelain and trypsin, along with the antioxidant flavonoid rutoside (rutin). Originally developed by Mucos Pharma under the brand name Phlogenzym, and marketed in India by Anglo-French Drugs & Industries, Rednil is indicated for the management of pre- and post-operative edema, acute pain, inflammation, traumatic injuries, and degenerative joint conditions such as osteoarthritis. The combination works synergistically: bromelain and trypsin break down inflammatory proteins, improve blood circulation, and promote tissue repair, while rutoside acts as an antioxidant to neutralize free radicals, strengthen capillaries, and reduce fluid leakage into tissues.
- Brand names
- Rednil
- Other names
- bromelain + rutoside trihydrate + trypsinbromelain + trypsin + rutosidetrypsin + bromelain + rutosidetrypsin + bromelain + rutoside trihydrate
02
Targets
AKR1C3 (Aldo-keto reductase family 1 member C3)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)CBR1 (Carbonyl reductase 1)NF-κBTNFA (Tumor necrosis factor alpha (soluble))PAR2 (Protease-activated receptor 2)
Beyond the preview
Go deeper on bromelain + rutoside + trypsin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bromelain + rutoside + trypsin.